THSTI-RBD-ELISA assay used for Pune COVID-19 serosurveillance study

Blood samples from 1664 consenting individuals, chosen as per the study design, were collected (from 20th July to 5th August) and processed to detect the presence of IgG antibodies against the receptor-binding domain (RBD) of the viral spike protein using the highly specific (100%) and sensitive (84.7%) THSTI-RBD-ELISA assay. IgG antibodies against the receptor-binding domain (RBD) of the viral spike protein was detected using the highly specific (100%) and sensitive (84.7%) THSTI-RBD-ELISA assay. This assay has been extensively characterized and compared with other commercially available tests for SARS-CoV2 IgG at DBT’s Translational Health Science and Technology Institute (THSTI), Faridabad.

The other participating organizations were Christian Medical College (CMC), Vellore, and the Pune Municipal Corporation (PMC). The survey specifically targeted selected high-incidence prabhags of Pune city. The study is supported by the Persistent Foundation.

On 17th August, Pune had more active cases of COVID-19 than Mumbai city. An epidemiological and serological surveillance of COVID-19 was conducted in Pune. The leading institutes were IISER Pune and Savitribai Phule Pune University (SPPU), Pune. THSTI's in-house Receptor-Binding Domain (RBD)-ELISA assay was used for testing the clinical samples.

The preliminary technical report (here) and summary of the initial findings are available on IISER Pune's website:

http://www.iiserpune.ac.in/userfiles/files/Pune_Serosurvey_summary_17_08_2020_ENGLIS
Detailed analysis and modelling of the data along with characterisation of the underlying immune response is ongoing and will be periodically updated.

Link:  https://science.thewire.in/the-sciences/antibody-test-kits-independent-verification-icmr-zydus-kavach-sensitivity/


Contact person:
Dr. Siuli Mitra,
E-mail: smitra@thsti.res.in